Video

Challenges in the Diagnosis of Neuroendocrine Tumors

For High-Definition, Click

When referred to academic centers, many patients who have been diagnosed with a neuroendocrine tumor (NET) have received a broad assortment of tests and assays. In general, Rodney F. Pommier, MD notes, the first task when seeing these patients is to narrow down the information based on clinical parameters.

To determine diagnosis patterns, Pommier analyzed 150 patients with abdominal carcinoids. Out of these patients, only 3.5% of patients were referred 3 months following their initial presentation. The remaining 96.5% of patients received a diagnosis on average 6.5 years after presentation and even up to 20 years in some cases. In general, these patients receive 35 different initial diagnoses.

This delay, Pommier feels, may be related to the fact that community physicians are not initially thinking about carcinoids as a potential diagnosis. This is due to a combination of the natural characteristics of the disease and a lack of general awareness.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Katherine L. Nathanson, MD
Dr Garrido-Laguna on the Safety of Daraxonrasib in KRAS G12X–Mutated PDAC
Aditya Bardia, MD, MPH, FASCO
Jin-Ji Yang, MD, of Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University
Richard T. Lee, MD, Cherng Family Director’s Chair, Center for Integrative Oncology, medical director, clinical professor, Supportive & Integrative Medicine, Department of Supportive Care Medicine, City of Hope
Rachna T. Shroff, MD, MS
Daneng Li, MD, associate professor, Department of Medical Oncology & Therapeutics Research, and co-director, Neuroendocrine Tumor Program, City of Hope
Dr Janjigian on 5-Year Data With Nivolumab Plus Chemotherapy in Gastric/GEJ/Esophageal Cancer
Katherine L. Nathanson, MD
Susumu Hijioka, MD, PhD